Fleischmann, M.; Bechwar, J.; Voigtländer, D.; Fischer, M.; Schnetzke, U.; Hochhaus, A.; Scholl, S.
Synergistic Effects of the RARalpha Agonist Tamibarotene and the Menin Inhibitor Revumenib in Acute Myeloid Leukemia Cells with KMT2A Rearrangement or NPM1 Mutation. Cancers 2024, 16, 1311.
https://doi.org/10.3390/cancers16071311
AMA Style
Fleischmann M, Bechwar J, Voigtländer D, Fischer M, Schnetzke U, Hochhaus A, Scholl S.
Synergistic Effects of the RARalpha Agonist Tamibarotene and the Menin Inhibitor Revumenib in Acute Myeloid Leukemia Cells with KMT2A Rearrangement or NPM1 Mutation. Cancers. 2024; 16(7):1311.
https://doi.org/10.3390/cancers16071311
Chicago/Turabian Style
Fleischmann, Maximilian, Julia Bechwar, Diana Voigtländer, Mike Fischer, Ulf Schnetzke, Andreas Hochhaus, and Sebastian Scholl.
2024. "Synergistic Effects of the RARalpha Agonist Tamibarotene and the Menin Inhibitor Revumenib in Acute Myeloid Leukemia Cells with KMT2A Rearrangement or NPM1 Mutation" Cancers 16, no. 7: 1311.
https://doi.org/10.3390/cancers16071311
APA Style
Fleischmann, M., Bechwar, J., Voigtländer, D., Fischer, M., Schnetzke, U., Hochhaus, A., & Scholl, S.
(2024). Synergistic Effects of the RARalpha Agonist Tamibarotene and the Menin Inhibitor Revumenib in Acute Myeloid Leukemia Cells with KMT2A Rearrangement or NPM1 Mutation. Cancers, 16(7), 1311.
https://doi.org/10.3390/cancers16071311
